GU Cancers 2021 | SEMS: surgery as first-line therapy for seminoma

Siamak Daneshmand, MD, Keck School of Medicine, Los Angeles, CA, outlines the findings of the Phase II SEMS trial (NCT02537548) investigating surgery as a first-line treatment in early metastatic seminoma. The trial enrolled 55 patients who underwent retroperitoneal lymph node dissection (RPLND). At a median follow-up of 24 months, the overall recurrence rate was 18%, with a median time to recurrence of 8 months. The two-year recurrence-free survival rate was 87% and overall survival was 100%. This interview took place during the 2021 Genitourinary Cancers Symposium.